ACC.15 Publication
Advertising Opportunities
SUNDAY
ACC.15 Daily
Closing Dates
64TH ANNUAL
SCIENTIFIC SESSION & EXPO
SAN DIEGO, CA
MARCH 16, 2015
STABILITY: Stabilization of Atherosclerotic
Plaque by Initiation of Darapladib Therapy
I
The official daily newspaper
of ACC.15, ACC’s 64th Annual
Scientific Session & Expo
n a new study, researchers have found that darapladib, a novel inflammation inhibitor, shows no primary endpoint advantage over placebo
in patients with chronic coronary heart disease with a high level of
background care. The data were released yesterday as part of ACC.14 and
simultaneously published in the New England Journal of Medicine.
The drug is designed to inhibit LpLate-Breaking PLA2, a biomarker of inflammation in
Clinical Trials blood vessels that is generally found on LDL
cholesterol. Since high Lp-PLA2 levels are
an associated risk factor for coronary heart
disease,Late-Breaking
and linked with vulnerable plaque, an unstable waxy buildup in
arterialClinical
walls thatTrials
is associated with heart attacks and strokes, the hope
was that darapladib would reduce the likelihood of such plaque resulting
in an artery-blocking clot.
In an international, phase III double-blind trial, 15,828 patients
with chronic coronary heart disease (median age 65-years-old) were randomly assigned to receive a daily 160-mg darapladib tablet or placebo.
With a median follow-up of 3.7 years darapladib showed no significant
benefit with 769 events (9.7 percent) compared with 819 events (10.4)
for the placebo. Despite not achieving its primary endpoint, a secondary
endpoint showed a nominally significant reduction in major coronary
events such as heart attack, an urgent need for angioplasty or bypass
surgery, or death. Those that took darapladib had a 10 percent relative
risk reduction, with 737 events (9.3 percent) in major coronary events
compared with 814 events (10.3 percent) in the placebo group.
See STABILITY, page 3
Late-Breaking
Clinical Trials
A. Michael Lincoff, MD, presented AleCardio results.
AleCardio:
Aleglitazar Fails to
Reduce CV Events
in Patients With
ACS and Diabetes
T
Yesterday’s joint ACC/Journal of the American Medical Association late-breaking clinical trials looked at new therapies and devices.
• Drive traffic to your booth
• Reach attendees and those
who missed the meeting
• Take advantage of post-show momentum
CHOICE: Self-Expandable vs. Balloon
Expandable Prostheses in Transfemoral
TAVR Patients
A
mong patients with high-risk aortic
taneously published in the Journal of the Ameristenosis undergoing transcatheter
can Medical Association (JAMA), looked at 241
aortic valve replacement (TAVR), the
high-risk patients with severe aortic stenosis
use of a balloon-expandable valve
and an anatomy suitable for the
Late-Breaking transfemoral TAVR procedure
resulted in a greater rate of device
Clinical Trials that were randomly assigned to
success than use of a self-expandable
valve, according to results from the
either receive a balloon-expandCHOICE trial released yesterday as part of
able valve or a self-expandable valve.
Late-Breaking
ACC.14.
Results found that device success ocClinical
Trials
The trial, the results of which were simulcurred
in 116 of 121 patients (95.9 percent) in
INSIDE
the balloon-expandable valve group compared
to 93 of 120 patients (77.5 percent) in the
self-expandable valve group (relative risk [RR],
1.24, 95 percent CI, 1.12-1.37, P < .001). According to study investigators, the difference
was attributed to a significantly lower frequency of residual more-than-mild aortic regurgitation (4.1 percent vs. 18.3 percent; RR, 0.23; 95
percent CI, 0.09-0.58; P < .001) and the less
frequent need for implanting more than 1 valve
(0.8 percent vs. 5.8 percent, P = .03) in the
balloon-expandable valve group.
Additional results showed cardiovascular
mortality at 30
days at 4.1 percent
See CHOICE, page 5
Late-Breaking
Clinical Trials
he phase III AleCardio trial of the drug
aleglitazar was brought to an early end
last year when data showed patients with
type 2 diabetes and recent acute coronary
syndrome treated with the medication began
developing higher rates of heart failure, kidney
events and gastrointestinal bleeding with no
offsetting cardiovascular benefits.
Late-Breaking
All other studies
Clinical Trials
implementing
the drug have
also been put to a halt. The data was presented
Late-Breaking
yesterday as part of ACC.14
and simultaneClinical
Trials
ously published in the Journal of the American
Medical Association.
Before its adverse effects were discovLate-Breaking
ered aleglitazar first garnered interest among
Clinical Trials
researchers for its influence on PPAR gamma
and alpha cellular receptors and the regulation
of glucose and lipids, which in turn could help
patients with type 2 diabetes battle sudden
blockages of blood flow to the heart. Randomly assigning 7,226 patients averaging 61
years of age to a daily 150 μg dose of aleglitazar
or placebo, the study was designed to continue
until 7,000 patients had been followed for 2.5
years and 950 primary endpoint events had
ACC.15 Daily Registration Issue
Ad space. . . . . . . . . 1/23/15
Final ad artwork. . . . 2/6/15
ACC.15 Daily Day 2 & 3
Ad space. . . . . . . . . 2/27/15
Final ad artwork. . . . 3/5/15
See ALECARDIO, page 5
Download the free ACC.14 eMeeting Planner mobile app
for the most up-to-date information.
MORE
3
3
ZIPES LECTURE
Jessica Mega, MD, MPH, will explore the
changing landscape of antithrombotic
therapy.
3
PREVENTION DAY-LONG
PROGRAM
Sessions take a broad patient-centered
approach aimed at members of the
cardiovascular team.
15
KANU AND DOCEY
CHATTERJEE LECTURE
ACC.14 Co-Chair Prediman Shah,
MD, will give the inaugural lecture,
which will focus on heart failure
prevention.
Today’s Schedule
5
Sports and Exercise Sessions
5
Heard on the Street
6
Interview with Incoming President O’Gara
8
Geriatric Sessions
10 Inaugural Braunwald Lecture
14 Women Sessions
On-site Issues: Published Saturday, Sunday and Monday
•C
ontains coverage of scientific presentations, educational sessions, award winners,
and other meeting activities, along with a daily schedule of key events
•D
istributed in bins located throughout the convention center each day
•S
aturday issue also distributed to attendees at registration and in official meeting bags
ACC.15 Daily Advertising Rates
ACC.15 Daily Publication Specs
10-7/8” x 15” (finished size)
ACC.15 Daily Newspaper rates
B/W Page
(3 issues)
Color Page
(3 issues)
Full Page
$13,500
$19,500
Jr. Page Island
$11,500
$17,500
3/4 Page
$11,000
$17,000
1/2 Page
$8,500
$14,000
1/4 Page
$8,000
$13,500
Ad Size
Net agency commission
Premium Rates*
Cover 4
$15,500
Cover 2
$13,500
Center Spread
Full Page
10.5” x 14”
• Newspaper ads do not bleed
• All dimensions are width x height
Junior Page
Island
7.5” x 10”
• Avoid text in 1” gutter area
Half Page
Horizontal
10.25” x 7”
1/2 Page
Vertical
5” x 14”
3/4 Page
Vertical
7” x 14”
1/4 Page
5” x 7”
$8,000
Front Cover Banner
$16,500
Cover Tip**
$20,500
Net agency commission
*On-site issue only packages available.
Call for pricing
**Per issue or $55,500 for all three on-site issues
Linsey Rosenthal
215-740-3174
[email protected]
Adam Sansolo
201-575-2242
[email protected]
ACC.15
Expo Daily
Digital File Specifications
64TH ANNUAL
SCIENTIFIC SESSION & EXPO
SAN DIEGO, CA
At ACC.15, this publication will place important Expo
information directly in the hands of attendees. Inserted into
the middle of the ACC.15 Daily newspaper, the Expo Daily
will be the only printed resource specifically highlighting
ACC.15 exhibitors, Learning Destination partners and Prime
Time Event hosts. The 12-page publication will be smaller
than the ACC.15 Daily newspaper (8 ½ x 11”), increasing its
visibility and encouraging attendees to pull it out and use as
a reference while at the show.
TODAY’S SCHEDULE
SUNDAY
March 16, 2014
Expo Hall, #2353
Get to Know Learning Destination
Lecturer James Januzzi, MD
9:45 a.m. – 10:45 a.m.
Treatment Options in Acute
Heart Failure: One Size Does
Not Fit All
Sponsored by Novartis Pharmaceuticals
Corporation
T
Industry-Expert
Theater™
12:45 p.m. – 1:45 p.m.
Closing the Gap on Thrombotic
Events
Sponsored by Janssen Pharmaceuticals,
Inc.
3:45 p.m. – 4:45 p.m.
The Importance of Treating
High Triglycerides
Sponsored by AstraZeneca
Innovation Stage
Expo Hall, #124
9:45 a.m. – 10:15 a.m.
Peptides in Post Discharge
Clinical Care Strategy
Sponsored by Roche Diagnostics
12:30 p.m. – 1:00 p.m.
A Discussion of Lutonix® Drug
Coated Balloon Technology
Sponsored by Bard
1:30 p.m. – 2:00 p.m.
Treating PAH and CTEPH
Sponsored by Bayer HealthCare
Pharmaceuticals
3:45 p.m. – 4:15 p.m.
Monoclonal Antibodies:
Three Decades of Innovation
and Progress
Sponsored by Sanofi Regeneron
Interactive Learning
Labs
Expo Hall, #1960
Educating to Help Improve
Patient Outcomes
Sponsored by Terumo Interventional
Systems
9:30 a.m. – 10:15 a.m.
10:30 a.m. – 11:15 a.m.
11:30 a.m. – 12:15 p.m.
12:30 p.m. – 1:15 p.m.
SEE PAGE 3
FOR MORE DETAILS!
oday, James Januzzi, MD, will be
presenting the lecture “Natriuretic Peptides
in Post Discharge Clinical Care Strategy”
at the Innovation Stage (#124) in the Expo Hall,
along with Ileana L. Piña, MD, MPH. Januzzi
is a professor of medicine at Harvard Medical
School and director of the
cardiac intensive care unit
at Massachusetts General
Hospital (MGH), and has
spent years with his team of
researchers focusing on the
evaluation and importance
of various biomarkers in
heart failure, including natriuretic peptides. Januzzi took
some time out of his busy
schedule to talk about his
career, research highlights
and hopes for the future.
How did you first enter the field of
cardiology?
around me in residency, it was a done deal.
That said, as I proceeded through residency and
began the search for fellowships, my lifelong
passion for clinical medicine began to tug at
me — being trained as a basic scientist, I knew
that I always wanted to be involved in something
related to the science of
heart disease, but wanted
to have a more clinical
foundation to the work that I
performed. I interviewed for
three fellowship programs
at Johns Hopkins, Brigham
and Women’s, and MGH.
Responding to the pull of
clinical cardiology, I chose
the position at MGH, to
study under master clinicians
like Roman DeSanctis,
MD, Dolph Hutter, MD,
and others.
Cardiology is a fascinating field in that
it affords so much opportunity to combine
the discipline of outstanding bedside clinical
evaluation with cutting edge science. For me,
there is no other field I could ever imagine being
in.
I have always wanted to be a physician. My
father is one of the best clinicians that I have ever
seen, and he inspired me to enter the field at a
What can you tell us about your
very young age. Following college graduation,
lecture? What are natriuretic
I did two years of research at the Rockefeller
peptides and why are they
University with Jan Breslow, MD, and during
important?
those two years, I focused on apolipoprotein
The natriuretic peptides, BNP and NT-proBNP,
gene regulation — the direct tie-in to cholesterol
are proteins released from the heart in the context
and vascular disease fascinated
of myocardial stress, as well as
me deeply. Breslow inspired me
other triggers. They rise in several
TODAY’S EXPO
to pursue a career in research,
HOURS
clinical diagnoses, but most notably
and I knew that cardiology was
they are considerably elevated in
the field for me. After graduating
9:30 a.m. – 4:45 p.m.
heart failure. The heart releases
from medical school, I matched
these peptides in an effort to trigger
a residency at the Brigham and
TODAY’S EXPO
dilation of the blood vessels, as well
Women’s Hospital, where my
BREAKS
as excretion of salt and water — in
chief of medicine was Eugene
9:30 a.m. – 10:45 a.m. essence balancing out the deranged
Braunwald, MD. Needless to say,
12:15 p.m. – 2:00 p.m.
physiology present in heart failure.
with the influence of Braunwald as
3:30 p.m. – 4:45 p.m.
We have shown that natriuretic
well as all of the giants of cardiology
continued on page 11
Contents
•
Expo floor plan
•
Exhibitor list alpha by company name
•
Exhibitor list by booth number
•
Stories highlighting that day’s Learning Destination and Prime Time Event
programming, as well as general Expo highlights
Distribution
•
Saturday, March 14: 28,000 copies inserted into attendee bags, and placed in
publication bins throughout the convention center
•
Sunday, March 15: 10,000 copies handed to attendees as they enter the convention
center, and placed in publication bins throughout the convention center
•
Monday, March 16: 10,000 copies handed to attendees as they enter the
convention center, and placed in publication bins throughout the convention center
ACC.15 Expo Daily Advertising Rates
Cover Ads (bundle 2, 3, & 4)
$35,000
Full page ad
$5,000
Half-page ad
$3,000
Quarter-page ad
$1,500
Closing Dates
ACC.15 Expo Daily
Day 1, 2 and 3:
Ad space. . . . . . . . . 1/23/15
Final ad artwork. . . . 2/6/15
Full Page Ads
Full Bleed
Half Page Ads
Full Bleed
Quarter Page Ads
Full Bleed
8.5 x 11 in.
8.5 x 5.5 in.
4.25 x 5.5 in.
Bleed
.125 in. outside trim edges
.125 in. outside trim edges
.125 in. outside trim edges
Safety
.5 in. inside trim edges
.5 in. inside trim edges
.5 in. inside trim edges
Non-Bleed Ads
Non-Bleed Ads
Non-Bleed Ads
7.5 x 10 in.
7.5 x 4.5 in.
3.5 x 4.5 in.
.5 in. inside from edges
.5 in. inside edges
.25 in. inside from edges
Ad Size
Safety
Submit ads as a high-resolution PDF
with advertiser name and issue date
in the filename following this format:
CompanyName_AdSize_Day_Placement.pdf
INTERNET/FTP DELIVERY OF ADS:
Please email Ari Mihos (amihos@
americanmedicalcomm.com) prior to
submitting a file via FTP.
Address: 108.170.95.250
Log in: cardiologyFTP
Password: cardiology
Folder: cardiologyFTP/CardioSource_
DailyNews
If desired, also email the PDF to Ari Mihos
([email protected]) if
the file is less than 10 MB
Ads may be submitted on CD-ROM.
WinZip and Stuffit are the only acceptable
compression techniques
For disks and/or proofs, please send to:
American Medical Communications
Ari Mihos
630 Madison Avenue
2nd Floor
Manalapan, NJ 07726
Phone: 732-490-5530
Advertising & Sales Office
American Medical
Communications
630 Madison Avenue
2nd Floor
Manalapan, NJ 07726
Phone: 732-490-5530
Fax 732-862-1116
ACC.15 Expo Daily Publication Specs
Trim
The ACC.15 Daily is produced and printed
direct-to-plate (DTP). Below is the file
format submission information for ads:
Account Managers:
Linsey Rosenthal
215-740-3174
[email protected]
Adam Sansolo
201-575-2242
[email protected]
John Baltazar, MBA
917-488-1528
[email protected]
Wrap-Up Issue: Published in CardioSource WorldNews,
April issue
• A special issue of the monthly tabloid magazine, mailed to the ACC’s US
membership of over 26,000 cardiovascular professionals
• Providing coverage of the most important news and information from ACC.15
• Ensures those cardiologists who could not attend ACC.15 are up-to-date on
the latest information
• C
over wrap programs available to target lists outside of circulation, e.g., family
practitioners, general practitioners and internists
JACC Supplement: Annual
Scientific Session Abstracts
The JACC abstracts issue and CDROM are ideal opportunities to reach
cardiology fellows, fellows in training and
ACC.15 attendees through an educational
tool that will be referred to repeatedly,
during and after the annual ACC Scientific
Session & Expo.
In Print
20,000 JACC abstract issues printed and
distributed in the official meeting bags at
ACC.15
ACC.15 Update eNewsletters
2015 net rates:
8 pages..........................................$40,000
6 pages........................................... $31,700
4 pages..........................................$22,350
2 pages............................................$11,950
1 page................................................$6,750
Recipients get a preview of pertinent
ACC.15 information, including registration
dates, keynote speakers, etc.
Recipients
Average Number of Recipients:
125,000 per email
Each preview email is sent to all ACC
members, and current and past ACC
annual meeting attendees
15% Average Open Rate
Distribution
Bi-weekly. . . . . . . . Sept 2014 – March 2015
Advertising Opportunities
Skyscraper. . . . . . . . . . . . . . . . . . . 160 x 600
Leaderboard. . . . . . . . . . . . . . . . . . 728 x 90
Net Cost. . . . . . . . . . $6,200 per banner slot
DVD
20,000 DVDs will be distributed via
client’s booth
• Single-Sponsored
• Full text of the abstracts
• Sponsor recognition on sleeve
Net cost..........................................$63,500
Linsey Rosenthal
215-740-3174
[email protected]
Adam Sansolo
201-575-2242
[email protected]
ABSTRACTS
Of Original Contributions
ABSTRACTS
Of Original Contributions
Presented at the American College
of Cardiology 65th Annual Scientific
Session and ACC-i2 with TCT